Jennifer Chan, MD, MPH, discussed the findings from the phase 3 CABINET trial leading to the FDA approval of cabozantinib in patients with neuroendocrine tumors.

Carcinoid tumors are part of a heterogeneous group of gastrointestinal and pancreatic endocrine tumors that are characterized by their capacity to produce and secrete hormones, 5-hydroxytryptamine ...

our doctors are working to improve the understanding and treatment of neuroendocrine tumors of the gastrointestinal system. Neuroendocrine tumors act quite differently — and, as a result, are managed ...

Background. A 48-year-old man presented with diarrhea, flushing, abdominal pain and weight loss of 10 kg over a 6-month period. He subsequently developed dyspnea on exertion. Diagnosis. Carcinoid ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...

The study was led by Jennifer Chan, MD, MPH, clinical director of the gastrointestinal cancer center and director of the program in carcinoid and neuroendocrine tumors at Dana-Farber Cancer Institute.

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

It isn’t easy to cope with carcinoid syndrome. People often think they have an idea of what having cancer is like, but NETs are different from other cancers. You might have ongoing symptoms and ...